Targets › L2
2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Ligand-gated cation channel that allows the movement of sodium and potassium monoatomic cations across cell membranes when activated by zinc (Zn2+), copper (Cu2+), and changes in pH. Could also transport cesium. (UniProt, Q401N2)
Open in Phaseline: the race on L2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Alabama at Birmingham | TA-CIN Recombinant fusion protein vaccine comprised of HPV16 L2, E7, and E6 proteins | E6, E7, L2 | Phase 1 | ASC-US | Dec 2027 |
| University of Alabama at Birmingham | pNGVL4aCRTE6E7L2 DNA plasmid vaccine encoding HPV16 E6, E7, and L2 antigens | E6, E7, L2 | Phase 1 | ASC-US | Dec 2027 |
ASC-US (2)
protein or peptide (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.